These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14984004)

  • 1. Advances in pathogenetic mechanisms of diabetic nephropathy.
    Nicholas SB
    Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1319-25. PubMed ID: 14984004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy.
    Ziyadeh FN
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S38-41. PubMed ID: 18842317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.
    Panchapakesan U; Chen XM; Pollock CA
    Nat Clin Pract Nephrol; 2005 Nov; 1(1):33-43. PubMed ID: 16932362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy.
    Ichinose K; Kawasaki E; Eguchi K
    Am J Nephrol; 2007; 27(6):554-64. PubMed ID: 17823503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
    Steinke JM; Mauer M;
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of TGF-beta in pathogenesis of diabetic nephropathy.
    Pantsulaia T
    Georgian Med News; 2006 Feb; (131):13-8. PubMed ID: 16575121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathogenesis of diabetic nephropathy.
    Dronavalli S; Duka I; Bakris GL
    Nat Clin Pract Endocrinol Metab; 2008 Aug; 4(8):444-52. PubMed ID: 18607402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.
    Daniel C; Schaub K; Amann K; Lawler J; Hugo C
    Diabetes; 2007 Dec; 56(12):2982-9. PubMed ID: 17878288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells.
    Miyauchi K; Takiyama Y; Honjyo J; Tateno M; Haneda M
    Diabetes Res Clin Pract; 2009 Feb; 83(2):190-9. PubMed ID: 19110334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
    Russo LM; del Re E; Brown D; Lin HY
    Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of TGF-beta/GLUT1 axis in susceptibility vs resistance to diabetic glomerulopathy in the Milan rat model.
    Ricci C; Iacobini C; Oddi G; Amadio L; Menini S; Rastaldi MP; Frasheri A; Pricci F; Pugliese F; Pugliese G
    Nephrol Dial Transplant; 2006 Jun; 21(6):1514-24. PubMed ID: 16449286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
    Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
    Lassila M; Jandeleit-Dahm K; Seah KK; Smith CM; Calkin AC; Allen TJ; Cooper ME
    J Am Soc Nephrol; 2005 Feb; 16(2):363-73. PubMed ID: 15625075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic nephropathy in patients with type 1 diabetes mellitus.
    Russell TA
    Nephrol Nurs J; 2006; 33(1):15-28; quiz 29-30. PubMed ID: 16538925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete remission of diabetic nephropathy in a type 1 diabetic patient with near-nephrotic range proteinuria and reduced renal function.
    Haraguchi K; Hara S; Ubara Y; Tanaka S; Nukui I; Shimura H; Ohashi K; Kobayashi T
    Diabetes Res Clin Pract; 2009 Mar; 83(3):295-9. PubMed ID: 19162360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TGF-beta 1 gene codon 10 polymorphism contributes to the genetic predisposition to nephropathy in Type 1 diabetes.
    Patel A; Scott WR; Lympany PA; Rippin JD; Gill GV; Barnett AH; Bain SC;
    Diabet Med; 2005 Jan; 22(1):69-73. PubMed ID: 15606694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice.
    Ichinose K; Maeshima Y; Yamamoto Y; Kinomura M; Hirokoshi K; Kitayama H; Takazawa Y; Sugiyama H; Yamasaki Y; Agata N; Makino H
    Diabetes; 2006 May; 55(5):1232-42. PubMed ID: 16644677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice.
    Dai C; Yang J; Bastacky S; Xia J; Li Y; Liu Y
    J Am Soc Nephrol; 2004 Oct; 15(10):2637-47. PubMed ID: 15466268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of diabetic nephropathy: from small print to centre stage.
    Cameron JS
    J Nephrol; 2006; 19 Suppl 10():S75-87. PubMed ID: 16874718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.